Page 13 - Processa Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...

/PRNewswire/ -- DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) was the recipient of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 123,500 shares, an increase of 31.9% from the May 15th total of 93,600 shares. Currently, 1.1% of the company’s shares are sold short. Based […]

Brokerages predict that Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) will announce earnings of ($0.26) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals posted earnings per share of ($0.20) in the same quarter last year, which would indicate a negative year-over-year growth rate of […]

BeyondSpring (NASDAQ:BYSI – Get Rating) and Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations. Valuation & Earnings This table compares BeyondSpring and Processa Pharmaceuticals’ […]